Researchers at Northeast Ohio Medical University (NEOMED) in the US have identified the link between areas of the brainstem - the ancient area that controls mood, sleep and metabolism - and detrimental changes to bone in a preclinical model of Alzheimer's disease (AD).
Alzheimer's has major social, emotional and financial consequences for patients and their families. Incurable and seemingly unstoppable, less than five per cent of AD cases are due to a clear genetic reason, so it is hard to predict who will be at risk for acquiring this devastating disease.
One's bones may be one of the earliest indicators of brain degeneration in Alzheimer's disease.
Reduced BMD, which sometimes leads to osteoporosis, translates to increased bone fracture risk, decreased quality of life, and increased mortality for AD patients.
More From This Section
Researchers suggest that early bone loss and serotonin deficiency in AD may tell us something very important about how we approach diagnosing and treating this disease.
"The findings of this study motivate us to explore the serotonin system as a potential new therapeutic target for this devastating disease," she said.
The study appears in the Journal of Alzheimer's Disease.